New combo aims to wipe out aggressive prostate tumors before surgery
NCT ID NCT05593497
First seen Mar 28, 2026 · Last updated Jun 19, 2026 · Updated 13 times
Summary
This phase 2 trial tests whether adding the targeted drug capivasertib to standard hormone therapy (abiraterone and leuprolide) before prostate removal surgery can shrink or destroy high-risk prostate cancers that have a PTEN gene loss. About 30 men with localized but aggressive prostate cancer will receive the drug combination for 16 weeks, then undergo surgery. The main goal is to see if the cancer is completely gone or reduced to a very small amount in the removed prostate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
James J. Peters VA Medical Center, Bronx, NY
RECRUITINGThe Bronx, New York, 10468-3904, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Ralph H. Johnson VA Medical Center, Charleston, SC
RECRUITINGCharleston, South Carolina, 29401-5703, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
-
South Texas Health Care System, San Antonio, TX
TERMINATEDSan Antonio, Texas, 78229-4404, United States
-
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
RECRUITINGWest Los Angeles, California, 90073-1003, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VA Portland Health Care System, Portland, OR
RECRUITINGPortland, Oregon, 97207-2964, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
VA Puget Sound Health Care System Seattle Division, Seattle, WA
RECRUITINGSeattle, Washington, 98108-1532, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capivasertib (a targeted drug) combined with abiraterone and leuprolide (hormone therapy)
What this could lead to
If successful, this approach could shrink or eliminate high-risk prostate tumors before surgery, potentially improving long-term outcomes for patients with PTEN loss.
What could go wrong
This is a small early-phase trial with only 30 participants, so results may not apply broadly. The drug combination may cause side effects, and it is not yet proven to be better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.